menu
    • menu
    [{"orgOrder":0,"company":"GC Cell","sponsor":"Rivaara Labs","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"INDIA","productType":"Cell and Gene therapy","year":"2022","type":"Licensing Agreement","leadProduct":"Autologous T-cell Immunotherapy","moa":"","graph1":"Oncology","graph2":"Approved","graph3":"GC Cell","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous","sponsorNew":"GC Cell \/ GC Cell","highestDevelopmentStatusID":"12","companyTruncated":"GC Cell \/ GC Cell"},{"orgOrder":0,"company":"GC Biopharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"SOUTH KOREA","productType":"Vaccine","year":"2022","type":"Not Applicable","leadProduct":"MG1111","moa":"","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Approved","graph3":"GC Biopharma","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"GC Biopharma \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"GC Biopharma \/ Not Applicable"},{"orgOrder":0,"company":"GC Biopharma","sponsor":"Catalyst Biosciences","pharmaFlowCategory":"D","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Large molecule","year":"2023","type":"Acquisition","leadProduct":"Marzeptacog Alfa","moa":"","graph1":"Genetic Disease","graph2":"Phase III","graph3":"GC Biopharma","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"GC Biopharma \/ GC Biopharma","highestDevelopmentStatusID":"10","companyTruncated":"GC Biopharma \/ GC Biopharma"},{"orgOrder":0,"company":"GC Biopharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"SOUTH KOREA","productType":"Vaccine","year":"2023","type":"Not Applicable","leadProduct":"Quadrivalent Influenza Vaccine","moa":"","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"GC Biopharma","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"","sponsorNew":"GC Biopharma \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"GC Biopharma \/ Not Applicable"},{"orgOrder":0,"company":"GC Biopharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"SOUTH KOREA","productType":"Large molecule","year":"2023","type":"Not Applicable","leadProduct":"Human Immune Globulin","moa":"","graph1":"Immunology","graph2":"Phase III","graph3":"GC Biopharma","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"GC Biopharma \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"GC Biopharma \/ Not Applicable"},{"orgOrder":0,"company":"GC Biopharma","sponsor":"EuBiologics","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"SOUTH KOREA","productType":"Vaccine","year":"2023","type":"Agreement","leadProduct":"Euvichol","moa":"","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"GC Biopharma","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Liquid","sponsorNew":"GC Biopharma \/ Eubiologics","highestDevelopmentStatusID":"12","companyTruncated":"GC Biopharma \/ Eubiologics"},{"orgOrder":0,"company":"GC Biopharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Rare Diseases and Disorders","country":"SOUTH KOREA","productType":"Large molecule","year":"2023","type":"Not Applicable","leadProduct":"GC1126A","moa":"","graph1":"Rare Diseases and Disorders","graph2":"Preclinical","graph3":"GC Biopharma","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Rare Diseases","amount2New":0,"dosageForm":"","sponsorNew":"GC Biopharma \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"GC Biopharma \/ Not Applicable"},{"orgOrder":0,"company":"GC Biopharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"SOUTH KOREA","productType":"Vaccine","year":"2023","type":"Not Applicable","leadProduct":"GC1109","moa":"","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"GC Biopharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Injection","sponsorNew":"GC Biopharma \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"GC Biopharma \/ Not Applicable"},{"orgOrder":0,"company":"GC Cell","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SOUTH KOREA","productType":"Cell and Gene therapy","year":"2024","type":"Not Applicable","leadProduct":"AB-201","moa":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"GC Cell","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"GC Cell \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"GC Cell \/ Not Applicable"},{"orgOrder":0,"company":"GC Biopharma","sponsor":"Novel Pharma","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"SOUTH KOREA","productType":"Large molecule","year":"2024","type":"Not Applicable","leadProduct":"Recombinant Human Heparan N-sulfatase","moa":"","graph1":"Genetic Disease","graph2":"Preclinical","graph3":"GC Biopharma","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"","sponsorNew":"GC Biopharma \/ Novel Pharma","highestDevelopmentStatusID":"4","companyTruncated":"GC Biopharma \/ Novel Pharma"},{"orgOrder":0,"company":"GC Biopharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"SOUTH KOREA","productType":"Large molecule","year":"2023","type":"Not Applicable","leadProduct":"Immune Globulin Intravenous, Human-stwk","moa":"","graph1":"Immunology","graph2":"Approved","graph3":"GC Biopharma","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"GC Biopharma \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"GC Biopharma \/ Not Applicable"},{"orgOrder":0,"company":"GC Biopharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"SOUTH KOREA","productType":"Large molecule","year":"2024","type":"Not Applicable","leadProduct":"Recombinant Human Heparan N-sulfatase","moa":"","graph1":"Genetic Disease","graph2":"Phase I","graph3":"GC Biopharma","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"","sponsorNew":"GC Biopharma \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"GC Biopharma \/ Not Applicable"},{"orgOrder":0,"company":"GC Biopharma","sponsor":"Novel Pharma","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"SOUTH KOREA","productType":"Large molecule","year":"2024","type":"Not Applicable","leadProduct":"Recombinant Human Heparan N-sulfatase","moa":"","graph1":"Genetic Disease","graph2":"Phase I","graph3":"GC Biopharma","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"","sponsorNew":"GC Biopharma \/ Novel Pharma","highestDevelopmentStatusID":"6","companyTruncated":"GC Biopharma \/ Novel Pharma"},{"orgOrder":0,"company":"GC Biopharma","sponsor":"Soleo Health","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"U.S.A","productType":"Large molecule","year":"2024","type":"Partnership","leadProduct":"Immune Globulin Intravenous, Human","moa":"","graph1":"Immunology","graph2":"Approved","graph3":"GC Biopharma","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"","sponsorNew":"GC Biopharma \/ GC Biopharma","highestDevelopmentStatusID":"12","companyTruncated":"GC Biopharma \/ GC Biopharma"},{"orgOrder":0,"company":"GC Biopharma","sponsor":"KabaFusion","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"SOUTH KOREA","productType":"Large molecule","year":"2024","type":"Partnership","leadProduct":"Immune Globulin Intravenous, Human","moa":"","graph1":"Immunology","graph2":"Approved","graph3":"GC Biopharma","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"","sponsorNew":"GC Biopharma \/ KabaFusion","highestDevelopmentStatusID":"12","companyTruncated":"GC Biopharma \/ KabaFusion"},{"orgOrder":0,"company":"GC Biopharma","sponsor":"Hanmi Pharmaceutical","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"SOUTH KOREA","productType":"Large molecule","year":"2024","type":"Not Applicable","leadProduct":"alpha-galactosidase A","moa":"","graph1":"Genetic Disease","graph2":"IND Enabling","graph3":"GC Biopharma","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"","sponsorNew":"GC Biopharma \/ Hanmi Pharmaceutical","highestDevelopmentStatusID":"5","companyTruncated":"GC Biopharma \/ Hanmi Pharmaceutical"},{"orgOrder":0,"company":"GC Biopharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"SOUTH KOREA","productType":"Large molecule","year":"2024","type":"Not Applicable","leadProduct":"Immune Globulin Intravenous, Human","moa":"","graph1":"Immunology","graph2":"Approved","graph3":"GC Biopharma","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"","sponsorNew":"GC Biopharma \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"GC Biopharma \/ Not Applicable"},{"orgOrder":0,"company":"GC Cell","sponsor":"PT Bifarma","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"SOUTH KOREA","productType":"Cell and Gene therapy","year":"2024","type":"Licensing Agreement","leadProduct":"CIK-based Cell Therapy","moa":"","graph1":"Oncology","graph2":"Phase III","graph3":"GC Cell","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"GC Cell \/ PT Bifarma","highestDevelopmentStatusID":"10","companyTruncated":"GC Cell \/ PT Bifarma"},{"orgOrder":0,"company":"GC Biopharma","sponsor":"Novelty Nobility","pharmaFlowCategory":"D","therapeuticArea":"Ophthalmology","country":"SOUTH KOREA","productType":"Large molecule","year":"2024","type":"Agreement","leadProduct":"ADC-based Therapy","moa":"","graph1":"Ophthalmology","graph2":"Undisclosed","graph3":"GC Biopharma","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"","sponsorNew":"GC Biopharma \/ Novelty Nobility","highestDevelopmentStatusID":"1","companyTruncated":"GC Biopharma \/ Novelty Nobility"},{"orgOrder":0,"company":"GC Biopharma","sponsor":"Novelty Nobility","pharmaFlowCategory":"D","therapeuticArea":"Ophthalmology","country":"SOUTH KOREA","productType":"Large molecule","year":"2024","type":"Agreement","leadProduct":"Antibody-based Therapy","moa":"","graph1":"Ophthalmology","graph2":"Discovery","graph3":"GC Biopharma","amount2":0,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"","sponsorNew":"GC Biopharma \/ GC Biopharma","highestDevelopmentStatusID":"2","companyTruncated":"GC Biopharma \/ GC Biopharma"},{"orgOrder":0,"company":"GC Biopharma","sponsor":"Novel Pharma","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"","productType":"Large molecule","year":"2024","type":"Not Applicable","leadProduct":"Recombinant Human Heparan N-sulfatase","moa":"","graph1":"Genetic Disease","graph2":"Phase I","graph3":"GC Biopharma","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"","sponsorNew":"GC Biopharma \/ Novel Pharma","highestDevelopmentStatusID":"6","companyTruncated":"GC Biopharma \/ Novel Pharma"},{"orgOrder":0,"company":"GC Biopharma","sponsor":"Immetas Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"U.S.A","productType":"Oligonucleotide","year":"2023","type":"Collaboration","leadProduct":"Undisclosed","moa":"CIDEB","graph1":"Immunology","graph2":"Discovery","graph3":"GC Biopharma","amount2":0,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"GC Biopharma \/ GC Biopharma","highestDevelopmentStatusID":"2","companyTruncated":"GC Biopharma \/ GC Biopharma"}]

    Find Clinical Drug Pipeline Developments & Deals by GC Biopharma

    Menu

    GC Biopharma

    EVENTS

    • Webinars & Exhibitions

    DIGITAL CONTENT

    DEVELOPMENTS

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            GC Biopharma

                            South Korea arrow
                            The Generic Rx Session
                            Not Confirmed

                            GC Biopharma

                            South Korea arrow
                            The Generic Rx Session
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Recombinant Human Heparan N-sulfatase

                            Therapeutic Area : Genetic Disease

                            Study Phase : Phase I

                            Sponsor : Novel Pharma

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            GC Biopharma Begins Global Phase I MPS IIIA Treatment Trial with First Dosed

                            Details : GC1130A' is a first-in-class treatment high-quality recombinant protein that is administered via ICV injection to bypass the BBB for the treatment of MPS IIIA.

                            Product Name : GC1130A

                            Product Type : Large molecule

                            Upfront Cash : Not Applicable

                            November 25, 2024

                            Lead Product(s) : Recombinant Human Heparan N-sulfatase

                            Therapeutic Area : Genetic Disease

                            Highest Development Status : Phase I

                            Sponsor : Novel Pharma

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            GC Biopharma

                            South Korea arrow
                            The Generic Rx Session
                            Not Confirmed

                            GC Biopharma

                            South Korea arrow
                            The Generic Rx Session
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : ADC-based Therapy

                            Therapeutic Area : Ophthalmology

                            Study Phase : Undisclosed

                            Sponsor : Novelty Nobility

                            Deal Size : Undisclosed

                            Deal Type : Agreement

                            DEALS_DEV arrow-down

                            GC Biopharma, Novelty Nobility Partner on Geographic Atrophy R&D

                            Details : Under the agreement terms, GC and Novelty will partner to jointly R&D antibody-based protein therapeutics for geographic atrophy, supporting all stages of the drug development lifecycle.

                            Product Name : Undisclosed

                            Product Type : Large molecule

                            Upfront Cash : Undisclosed

                            October 28, 2024

                            Lead Product(s) : ADC-based Therapy

                            Therapeutic Area : Ophthalmology

                            Highest Development Status : Undisclosed

                            Sponsor : Novelty Nobility

                            Deal Size : Undisclosed

                            Deal Type : Agreement

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            03

                            GC Biopharma

                            South Korea arrow
                            The Generic Rx Session
                            Not Confirmed

                            GC Biopharma

                            South Korea arrow
                            The Generic Rx Session
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Antibody-based Therapy

                            Therapeutic Area : Ophthalmology

                            Study Phase : Discovery

                            Recipient : Novelty Nobility

                            Deal Size : Undisclosed

                            Deal Type : Agreement

                            DEALS_DEV arrow-down

                            GC Biopharma And Novelty Nobility Team Up for Geographic Atrophy R&D

                            Details : GC Biopharma and Novelty Nobility established a partnership to jointly research and develop antibody-based protein therapeutics for GA throughout all stages of the drug development lifecycle.

                            Product Name : Undisclosed

                            Product Type : Large molecule

                            Upfront Cash : Undisclosed

                            October 28, 2024

                            Lead Product(s) : Antibody-based Therapy

                            Therapeutic Area : Ophthalmology

                            Highest Development Status : Discovery

                            Recipient : Novelty Nobility

                            Deal Size : Undisclosed

                            Deal Type : Agreement

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            04

                            GC Cell

                            South Korea arrow
                            The Generic Rx Session
                            Not Confirmed

                            GC Cell

                            South Korea arrow
                            The Generic Rx Session
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : CIK-based Cell Therapy

                            Therapeutic Area : Oncology

                            Study Phase : Phase III

                            Sponsor : PT Bifarma

                            Deal Size : Undisclosed

                            Deal Type : Licensing Agreement

                            DEALS_DEV arrow-down

                            GC Cell and PT Bifarma Sign Licensing Deal For Immuncell-LC in Indonesia

                            Details : Bifarma will be granted the exclusive rights to develop, manufacture, and commercialize Immuncell-LC, an anti-cancer immune cell therapy, for 15 years.

                            Product Name : Immuncell-LC

                            Product Type : Cell and Gene therapy

                            Upfront Cash : Undisclosed

                            September 10, 2024

                            Lead Product(s) : CIK-based Cell Therapy

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase III

                            Sponsor : PT Bifarma

                            Deal Size : Undisclosed

                            Deal Type : Licensing Agreement

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            05

                            GC Biopharma

                            South Korea arrow
                            The Generic Rx Session
                            Not Confirmed

                            GC Biopharma

                            South Korea arrow
                            The Generic Rx Session
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Immune Globulin Intravenous, Human

                            Therapeutic Area : Immunology

                            Study Phase : Approved

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            GC Biopharma Launches ALYGLO™ for Primary Humoral Immunodeficiency in the U.S.

                            Details : ALYGLO (immune globulin intravenous, human-stwk) is a 10% immune globulin liquid for intravenous injection, indicated for the treatment of primary humoral immunodeficiency (PI) in adults.

                            Product Name : Alyglo

                            Product Type : Large molecule

                            Upfront Cash : Not Applicable

                            September 09, 2024

                            Lead Product(s) : Immune Globulin Intravenous, Human

                            Therapeutic Area : Immunology

                            Highest Development Status : Approved

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            06

                            GC Biopharma

                            South Korea arrow
                            The Generic Rx Session
                            Not Confirmed

                            GC Biopharma

                            South Korea arrow
                            The Generic Rx Session
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : alpha-galactosidase A

                            Therapeutic Area : Genetic Disease

                            Study Phase : IND Enabling

                            Sponsor : Hanmi Pharmaceutical

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            GC Biopharma and Hanmi Receive IND Clearance for Phase 1/2 Trial in the US

                            Details : GC1134A/HM15421 is a long-acting alpha-galactosidase that can be administered subcutaneously once a month in patients with fabry disease, also to improve patient's convenience.

                            Product Name : GC1134A

                            Product Type : Large molecule

                            Upfront Cash : Not Applicable

                            September 03, 2024

                            Lead Product(s) : alpha-galactosidase A

                            Therapeutic Area : Genetic Disease

                            Highest Development Status : IND Enabling

                            Sponsor : Hanmi Pharmaceutical

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            07

                            GC Biopharma

                            South Korea arrow
                            The Generic Rx Session
                            Not Confirmed

                            GC Biopharma

                            South Korea arrow
                            The Generic Rx Session
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Immune Globulin Intravenous, Human

                            Therapeutic Area : Immunology

                            Study Phase : Approved

                            Sponsor : KabaFusion

                            Deal Size : Undisclosed

                            Deal Type : Partnership

                            DEALS_DEV arrow-down

                            KabaFusion Selected by GC Biopharma USA as Limited Distribution Partner for ALYGLO™

                            Details : GC Biopharma partners with KabaFusion for the distribution to provide Alyglo (Immune Globulin Intravenous, Human) for treating primary humoral immunodeficiency for Adults, 17 years and older.

                            Product Name : Alyglo

                            Product Type : Large molecule

                            Upfront Cash : Undisclosed

                            July 30, 2024

                            Lead Product(s) : Immune Globulin Intravenous, Human

                            Therapeutic Area : Immunology

                            Highest Development Status : Approved

                            Sponsor : KabaFusion

                            Deal Size : Undisclosed

                            Deal Type : Partnership

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            08

                            GC Biopharma

                            South Korea arrow
                            The Generic Rx Session
                            Not Confirmed

                            GC Biopharma

                            South Korea arrow
                            The Generic Rx Session
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Immune Globulin Intravenous, Human

                            Therapeutic Area : Immunology

                            Study Phase : Approved

                            Recipient : Soleo Health

                            Deal Size : Undisclosed

                            Deal Type : Partnership

                            DEALS_DEV arrow-down

                            Soleo Health Selected as Specialty Pharmacy for ALYGLO™ for Adults with PI

                            Details : Soleo partnership with GC Biopharma to dispense Alyglo (Immune Globulin Intravenous, Human-stwk) 10% Liquid for treating Adults with Primary Humoral Immunodeficiency.

                            Product Name : Alyglo

                            Product Type : Large molecule

                            Upfront Cash : Undisclosed

                            July 16, 2024

                            Lead Product(s) : Immune Globulin Intravenous, Human

                            Therapeutic Area : Immunology

                            Highest Development Status : Approved

                            Recipient : Soleo Health

                            Deal Size : Undisclosed

                            Deal Type : Partnership

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            09

                            GC Biopharma

                            South Korea arrow
                            The Generic Rx Session
                            Not Confirmed

                            GC Biopharma

                            South Korea arrow
                            The Generic Rx Session
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Recombinant Human Heparan N-sulfatase

                            Therapeutic Area : Genetic Disease

                            Study Phase : IND Enabling

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            FDA Grants Fast Track Designation to GCBP and Novel Pharma's GC1130A

                            Details : GC1130A (recombinant human heparan N-sulfatase) is an intracerebroventricular enzyme replacement therapy candidate. It is being evaluated for the treatment of sanfilippo syndrome type A.

                            Product Name : GC1130A

                            Product Type : Large molecule

                            Upfront Cash : Not Applicable

                            June 10, 2024

                            Lead Product(s) : Recombinant Human Heparan N-sulfatase

                            Therapeutic Area : Genetic Disease

                            Highest Development Status : IND Enabling

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            10

                            GC Biopharma

                            South Korea arrow
                            The Generic Rx Session
                            Not Confirmed

                            GC Biopharma

                            South Korea arrow
                            The Generic Rx Session
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Recombinant Human Heparan N-sulfatase

                            Therapeutic Area : Genetic Disease

                            Study Phase : Preclinical

                            Sponsor : Novel Pharma

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            GC Biopharma/Novel Pharma's Sanfilippo Syndrome Treatment Obtains FDA IND Approval

                            Details : GC1130A (recombinant human heparan N-sulfatase), is an intracerebroventricular (ICV) enzyme replacement therapy candidate under investigation for the treatment of sanfilippo syndrome.

                            Product Name : GC1130A

                            Product Type : Large molecule

                            Upfront Cash : Not Applicable

                            May 20, 2024

                            Lead Product(s) : Recombinant Human Heparan N-sulfatase

                            Therapeutic Area : Genetic Disease

                            Highest Development Status : Preclinical

                            Sponsor : Novel Pharma

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth